Glaxosmithkline | GSK - Equity Capital And Reserves


Glaxosmithkline reported GBP17.42B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -5.94B 721M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
Aurora Cannabis CAD 511.83M 24.53M Mar/2026
Bausch Health Companies USD -802M 1.26B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Canopy Growth CAD 697.59M 60.58M Mar/2026
Corcept Therapeutics USD 705.78M 67.79M Jun/2026
Drreddys Laboratories INR 380.46B 376.31B Mar/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
Glaxosmithkline GBP 17.42B 4.64B Mar/2026
J&J USD 84.97B 3.78B Jun/2026
Merck USD 41.93B 3.94B Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Pacira USD 671.98M 18.08M Jun/2026
Perrigo USD 2.52B 17M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Phibro Animal Health USD 361.83M 29.47M Mar/2026
Prestige Brands USD 1.92B 29.2M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sanofi EUR 69.57B 3.24B Jun/2026
Supernus Pharmaceuticals USD 1.03B 45.58M Jun/2026
Takeda JPY 7.56T 215.7B Jun/2026
Teva Pharmaceutical Industries USD 7.75B 475M Jun/2026
Zoetis USD 3.15B 85M Jun/2026